I am a
Home I AM A Search Login

Papers of the Week

2021 Apr

CNS Spectr



Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintenance in Patients with Tardive Dyskinesia.


Wilhelm A, Anderson KE, Fernandez HH, Barkay H, Chaijale N, Send AF, Savola J-M, Gordon M F
CNS Spectr. 2021 Apr; 26(2):164-180.
PMID: 33928883.


Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly by 6 mg/day, from 12 to 48 mg/day, based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during titration versus maintenance.